31881-86-4

Basic information

• Product Name: 2-(2-bromo-4-methylphenyl)acetic acid
• Synonyms: 2-(2-bromo-4-methylphenyl)acetic acid
• CAS NO: 31881-86-4
• Molecular Weight: 229.073
• Mol File: 31881-86-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(2-bromo-4-methylphenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-bromo-4-methylphenyl)acetic acid(31881-86-4)
• EPA Substance Registry System: 2-(2-bromo-4-methylphenyl)acetic acid(31881-86-4)

Safety Data

• Hazardous Substances Data: 31881-86-4(Hazardous Substances Data)

Upstream product

• 75366-14-2 1-(bromomethyl)-2-bromo-4-methylbenzene 
• 1069114-80-2 (2-bromo-4-methyl-phenyl)-acetonitrile 
• 1241405-24-2 (2-bromo-4-methylphenyl)acetaldehyde 

Downstream Products

• 1069114-83-5 methyl 2-(2-bromo-4-methylphenyl)acetate 

Relevant articles and documents

Chiral Magnesium Bisphosphate-Catalyzed Asymmetric Double C(sp3)-H Bond Functionalization Based on Sequential Hydride Shift/Cyclization Process

Described herein is a chiral magnesium bisphosphate-catalyzed asymmetric double C(sp3)-H bond functionalization triggered by a sequential hydride shift/cyclization process. This reaction consists of stereoselective domino C(sp3)-H bond functionalization: (1) a highly enantio- and diastereoselective C(sp3)-H bond functionalization by chiral magnesium bisphosphate (first [1,5]-hydride shift), and (2) a highly diastereoselective C(sp3)-H bond functionalization by an achiral catalyst (Yb(OTf)3, second [1,5]-hydride shift).

Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl) methyl]phenyl}propanoic acid: Nonsteroidal anti-inflammatory drugs with low membrane permeabilizing and gastric lesion-producing activities

We previously proposed that membrane permeabilization activity of NSAIDs is involved in NSAID-induced gastric lesions. We here synthesized derivatives of loxoprofen that have lower membrane permeabilization activity than other NSAIDs. Compared to loxoprofen, the derivatives 10a and 10b have lower membrane permeabilization activity and their oral administration produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 10a and 10b are likely to be therapeutically beneficial as safer NSAIDs.